Control recipients (PERKF/F) receiving leukemia cells from primary ICN1 mice developed secondary leukemia within 2 weeks while PERK-depleted mice showed reduced leukemia burden in the marrow and in the spleen (Fig. 4A). This evidence concerns the gene EIF2AK3 and leukemia.